The financial windfall enabled the foundation to give away a jaw-dropping $1.3 billion to Christian causes in 2025
Emerging evidence also suggests the potential to lower cardiovascular risks, highlighting its role in diabetes management (Epelde 2024
this protects your teeth and the camera
For a complete list of donation requirements, please visit the plasma center closest to you
2 In separate clinical studies of adults with overweight or obesity, about 1 in 4 taking Wegovy oral semaglutide 25 mg (64 weeks), about 1 in 3 taking Wegovy injection 2.4 mg (68 weeks), and about 1 in 2 taking Wegovy injection 7.2 mg (72 weeks) lost 3 Membership required, fee not included, and billed separately
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events